Commercial real estate spends millions on AI with little to show

Commercial real estate has entered the strange part of the AI cycle. Nearly everyone is experimenting, nearly everyone is paying attention, and many firms are spending real money on tools that have not yet changed how the business actually runs. According to Commercial Observer, the reason is not that AI lacks power. The reason is that the work itself resists easy automation.

The pattern is not unique to real estate. Across industries, firms are buying in before they know what they are buying. Roblox is deploying facial age estimation technology to verify users, moving beyond checkbox attestations that the company now considers inadequate. The Verge reports that Roblox's vice president of safety product policy said the new video selfie approach will "continue to get better," but the company invited a group of kids to test the system and the results were mixed.

The disconnect is instructive. AI is being deployed not because it works well, but because the alternative feels worse. In real estate, that means underwriting tools that do not yet replace analysts. In consumer platforms, it means age verification that may be no more reliable than the checkbox it replaces, but signals that the company is doing something.

Meanwhile, capital is moving. PE Hub reports that Advent-backed Nuvei is acquiring Payoneer in a $2.75 billion take-private deal, a reminder that payment infrastructure still trades at meaningful multiples even as adjacent technology investments struggle to prove ROI. Foundation Alloy raised $22 million to scale production of metals processed through mechanical deformation rather than heat, targeting military drones, luxury goods, and kitchen tools. TechCrunch notes the startup is betting that material science can command a premium where software has not.

In pharma, the cycle looks different. Johnson & Johnson reported positive results for Talvey in earlier-stage multiple myeloma, supporting expansion of the immunotherapy's label. Eli Lilly scored early positive data for a new JAK inhibitor acquired through its purchase of Ajax, with BioPharma Dive noting the drug showed encouraging effects in hard-to-treat myelofibrosis and could compete with Incyte's Jakafi. Both are examples of clinical bets that take years to pay out but follow a known playbook.

The contrast is sharp. Real estate firms are spending now on tools that may work later. Pharma firms are spending now on tools that will work in five years, and the market knows how to price that. The difference is not optimism. It is certainty about what comes next.